Holen Sie sich die Stockscreener-App
43.78
2.17%
-0.97
Handel nachbörslich:
43.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
14.57%
108.83
|
127.39 | 98.05 | 108.31 | 100.50 |
Operating Expenses
|
9.92%
274.18
|
249.44 | 243.15 | 256.27 | 254.60 |
| Benefits Costs and Expenses |
9.74%
279.06
|
254.28 | 257.05 | 267.40 | 263.97 |
| Costs And Expenses |
9.74%
279.06
|
254.28 | 257.05 | 267.40 | 263.97 |
| Operating Income/Loss |
35.48%
-165.35
|
-122.05 | -145.10 | -147.96 | -154.10 |
| Income/Loss From Continuing Operations Before Tax |
34.15%
-170.23
|
-126.89 | -159.00 | -159.10 | -163.48 |
| Income Tax Expense/Benefit |
112.29%
0.455
|
-3.702 | 0.65 | 0.732 | 0.495 |
| Income/Loss From Continuing Operations After Tax |
38.55%
-170.68
|
-123.19 | -159.65 | -159.83 | -163.97 |
|
Net Income/Loss
|
38.55%
-170.68
|
-123.19 | -159.65 | -159.83 | -163.97 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
3,198%
84.29
|
2.5561 | 71.66 | 70.90 | 70.37 |
| Diluted Average Shares |
3,198%
84.29
|
2.5561 | 71.66 | 70.90 | 70.37 |
| Basic Earnings Per Share |
40.97%
-2.03
|
-1.44 | -2.23 | -2.25 | -2.33 |
| Diluted Earnings Per Share |
40.97%
-2.03
|
-1.44 | -2.23 | -2.25 | -2.33 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):